Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

74.01 -0.33 (-0.44%)
Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,462,329
Open 74.56
Bid (Size) 73.99 (2)
Ask (Size) 74.19 (1)
Prev. Close 74.34
Today's Range 73.70 - 74.82
52wk Range 57.00 - 148.15
Shares Outstanding N/A
Dividend Yield 2.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Do Investors Really Feel About Novo Nordisk?
Via Benzinga
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
This dark horse candidate has emerged to take significant share in the weight-loss drugs space. 
Via Investor's Business Daily
Exposures Product Safety

Performance

YTD
-15.4%
-15.4%
1 Month
+10.4%
+10.4%
3 Month
-6.3%
-6.3%
6 Month
-30.2%
-30.2%
1 Year
-47.4%
-47.4%

More News

Read More
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - A Strong Candidate for Value Investors
Via Chartmill
Why Scholar Rock Shares Are Soaring Today
Via The Motley Fool
Topics Stocks
Exposures US Equities
US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies
Via Stocktwits
Topics Lawsuit
Exposures Financial Legal Product Safety
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Via Benzinga
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Novo Nordisk Stock Sank by Nearly 4% Today
Via The Motley Fool
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
Via FinancialNewsMedia
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
1 Growth Stock Down 9% to Buy Right Now
Via The Motley Fool
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Why Novo Nordisk Stock Pumped Higher on Thursday
Via The Motley Fool
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking
Via Stocktwits
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills
Via Benzinga
4 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock?
Via The Motley Fool
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
Via Benzinga
Nvidia Extends AI Reach In Europe With Alliances
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
Via Stocktwits
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 74.01
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 06/18/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.